Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | ALDH1A3 | P47895 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955168 | 1.00 | ALDH1A1 (0.64) | ALDH1A1VCAM1ALDH1A3HSD17B10CYP2A6 | |
| Ethane SCHEMBL2153562 | 0.98 | ALDH1A1 (0.61) | ALDH1A1VCAM1ALDH1A3HSD17B10CYP2A6 | |
| SCHEMBL8802168 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TSHRTDP1TTR | |
| SCHEMBL2153494 | 0.84 | ALDH1A1 (0.47) | ALDH1A1VCAM1ALDH1A3CYP2A6ALDH3A1 | |
| SCHEMBL29952189 | 0.82 | ALDH1A1 (0.64) | ALDH1A1VCAM1ALDH1A3HSD17B10CYP2A6 | |
| SCHEMBL980697 | 0.82 | ALDH1A1 (0.64) | ALDH1A1VCAM1ALDH1A3HSD17B10CYP2A6 | |
| SCHEMBL2154531 | 0.80 | CYP1A2 (0.44) | ALDH1A1VCAM1ALDH1A3ALDH3A1 | |
| SCHEMBL27875847 | 0.80 | ALDH1A1 (0.40) | ALDH1A1VCAM1ALDH1A3ALDH3A1PTGS2 | |
| SCHEMBL18346011 | 0.79 | XDH (0.48) | ALDH1A1VCAM1PTGS2KDM4ELMNA | |
| SCHEMBL18346009 | 0.79 | XDH (0.48) | ALDH1A1VCAM1PTGS2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050112-A | DOPO derivative containing benzazepine as well as preparation method and application thereof | 西华大学 | 2023-11-14 | — | — | CN | claimed |
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | claimed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | claimed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | claimed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | claimed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | claimed |
| CN-119707903-A | Isopentenyl flavonoid compound and preparation method and application thereof | 中山大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-119569635-A | Biaryl ring inhibitors targeting c-Myc proteins | 上海深势唯思科技有限责任公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-117362288-A | Harmine derivative topoisomerase I inhibitor, preparation method and medical application thereof | 中国药科大学 | 2024-01-09 | — | — | CN | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| CN-111344281-B | Potassium channel inhibitors substituted benzimidazoles | 阿塞西翁制药公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-117050112-A | DOPO derivative containing benzazepine as well as preparation method and application thereof | 西华大学 | 2023-11-14 | — | — | CN | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-0168003-A1 | Oxindol compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-15 | — | — | EP | disclosed |
| US-4514401-A | CARDIOTONICS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-04-30 | — | — | US | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0126635-A2 | Novel oxindole derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-11-28 | — | — | EP | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | ALDH1A1 4776/4885VCAM1 4470/4885ALDH1A3 4660/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | ALDH1A1 4776/4885VCAM1 4470/4885ALDH1A3 4660/4885 |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | VIP, PEPD, NRDC | ALDH1A1 4861/4885VCAM1 1436/4885ALDH1A3 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.